Elacyt (Clavis Pharma) fails Phase III trial for AML
Clavis Pharma announced results of the Phase III CLAVELA study investigating Elacyt (elacytarabine) in patients with relapsed or refractory Acute Myeloid Leukaemia (AML). The trial showed that there was no significant difference in overall survival between the two arms where patients were randomised to receive either elacytarabine or investigator's choice of treatment. Median survival in the elacytarabine arm was 3.5 months, compared to 3.3 months in the control arm, with a hazard ratio of 0.97. Adverse events were comparable between the two arms, and no meaningful differences were observed in any subgroup analyses.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.